Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Alamar Biosciences, Inc.NASDAQ: ALMR
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization of $1.13M in Q2 FY2026
Q2 FY2026 depreciation & amortization was $1.13M.
Context
- Depreciation & amortization amounted to 5.2% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.86M USD
- Year-over-year change
- —
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.86M | — |
Depreciation & Amortization vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 depreciation & amortization of $3.86M is the smallest of the 9 companies compared; the peer median is $14.34M.
- Depreciation & amortization amounts to 5.2% of revenue for ALMR, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $96.75M | -8.8% | -3.2% | 7.9% | |
| LTM Jun 2026 | $45.93M | +12.6% | +9.9% | 7.4% | |
| LTM Sep 2026 | $26.48M | +6.6% | -3.3% | 5.8% | |
| LTM Mar 2026 | $17.69M | -95.7% | +181.5% | 11.1% | |
| LTM Mar 2026 | $10.99M | -30.6% | -51.5% | 12.7% | |
| LTM Mar 2026 | $6.32M | -1.1% | +23.7% | — | |
| LTM Mar 2026 | $4.89M | -22.2% | +22.5% | 32.5% | |
| LTM Mar 2026 | $4.76M | +6.9% | +19.9% | 257.1% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $3.86M | — | — | 5.2% |
| Peer median (excluding ALMR) | $14.34M | -5.0% | +14.9% | 11.1% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (29.82M) |
| Depreciation & Amortization | 3.86M |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.87M |
| Change in Working Capital | (32.57M) |
| Accounts Receivables | (5.5M) |
| Inventory | (23.78M) |
| Accounts Payables | (572K) |
| Other Working Capital | (2.72M) |
| Other Non-Cash Items | 2.05M |
| Operating Cash Flow | (53.61M) |
| Capital Expenditures | (6.38M) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (4.94M) |
| Sales of Investments | 57.5M |
| Other Investing Activities | (1.01M) |
| Investing Cash Flow | 46.18M |
| Debt Repayment | 10M |
| Common Stock Issued | 1.49M |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | (657K) |
| Financing Cash Flow | 10.84M |
| Effect of Forex Changes | (172K) |
| Net Change in Cash | 3.23M |
| Free Cash Flow | (59.99M) |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.